Latest Prostate Cancer News

Page 5 of 5

Telix Surpasses FY24 Revenue Targets with US$142M Q4 Surge

Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.

Ada Torres

13 Jan 2025

Top